We expect modest Q1 sales growth of 1% for Suominen, driven mainly by price increases following high...
Redeye strengthens its positive view of Formpipe following the Q1 report.
Føroya Banki reported a solid Q1, as profit before loan losses landed at DKK 56m, DKK 3m (7%) better...
Sales down 16% y-o-y as EEs remained flat q-o-q, 7% below us We push forward recovery a bit, but wil...
Redeye comments on BioInvent’s first quarter in 2025.
Redeye shares its initial take on Physitrack’s Q1 2025 results.
Det var en väntat stark och stabil rapport som Eastnine kom med för det första kvartalet.
Redeye provides a brief comment on the latest expansion of the Digital Extremes development agreemen...
Q1 profit before loan losses came in at DKK 56m, DKK 3m (6%) above our estimate.
Visserligen föll Aixias nettoomsättning till 85,9 (205,6) mkr, men fjolårssiffran innehåller jätteor...
Redeye shares its initial take on Modelon’s Q1 2025 results, with ARR slightly below expectations wh...
Sales -7% (EEs -9%, SCs +15%), EBIT -19% vs. our estimates Opex in line, low equipment sales only a ...
Beijer Alma levererar en bra kvartalsrapport som visar på både organisk och förvärvsdriven tillväxt ...
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phas...
Redeye comments on Evolution’s Q1-results which were somewhat weaker than expected, driven by soft r...
Egetis delivered sales along expectations and more importantly, the German launch is underway follow...
'25e sales cut by 5%, three system deliveries for '25e (prev.
Redeye updates its view on M.O.B.A. Network following the Q1 2025 report.
Redeye updates its estimates and valuation for Tradedoubler following the Q1 2025 report.
Redeye updates its estimates and valuation following MedCap releasing its Q1 2025 report.
